Modality
mRNA
MOA
GLP-1/GIP
Target
TIGIT
Pathway
DDR
Endometrial CaIPF
Development Pipeline
Preclinical
~Aug 2017
→ ~Nov 2018
Phase 1
~Feb 2019
→ ~May 2020
Phase 2
Aug 2020
→ Oct 2031
Phase 2Current
NCT03019567
1,533 pts·IPF
2021-07→2026-03·Not yet recruiting
NCT04836138
569 pts·Endometrial Ca
2020-08→2031-10·Completed
2,102 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-03-103w agoPh3 Readout· IPF
2031-10-215.6y awayPh3 Readout· Endometrial Ca
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2/3
Complet…
P2/3
Not yet…
Catalysts
Ph3 Readout
2026-03-10 · 3w ago
IPF
Ph3 Readout
2031-10-21 · 5.6y away
Endometrial Ca
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03019567 | Phase 2/3 | IPF | Not yet recr... | 1533 | OS |
| NCT04836138 | Phase 2/3 | Endometrial Ca | Completed | 569 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| Miritinib | Neurocrine | Phase 3 | TIGIT | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| UTH-9370 | United Therapeutics | NDA/BLA | TIGIT | |
| COR-9456 | Corcept | Preclinical | TIGIT |